TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating on April 21.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tyler Van Buren has given his Buy rating due to a combination of factors related to Gilead’s updated outlook ahead of Q1:26 results. He raised projections for the company’s HIV and liver disease businesses, as well as for in-process research and development, indicating improved confidence in key growth and innovation drivers that support stronger earnings power over time.
At the same time, he incorporated management’s guidance for a year-over-year decline in cell therapy revenue, adjusting assumptions to a 10% contraction in that segment. Even after this more conservative stance on cell therapy, his non-GAAP EPS forecast increased to $1.90 and he maintained the existing price target, suggesting that upside from core franchises more than offsets the headwinds and justifies a Buy recommendation on the shares.
In another report released on April 21, Bernstein also maintained a Buy rating on the stock with a $160.00 price target.